Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: Evidence from a dopamine transporter imaging study

Journal of Neural Transmission

Volumn 111, Issue 8, 2004, Pages 1065-1073

  Ceravolo, R ^a   Volterrani, D ^a   Gambaccini, G ^a   Bernardini, S ^a   Rossi, C ^a   Logi, C ^a   Tognoni, G ^a   Manca, G ^a   Mariani, G ^a   Bonuccelli, U ^a   Murri, L ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Alzheimer's disease; Dopamine transporter imaging; Parkinsonism

Indexed keywords

COCAINE DERIVATIVE; DOPAMINE TRANSPORTER; LIGAND; N (3 IODOPROPEN 2 YL) 2BETA CARBOXYMETHYL 3BETA 4 CHLOROPHENYLTROPANE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IN VIVO STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; OCCIPITAL LOBE; PARKINSONISM; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 3843115654     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0140-0     Document Type: Article

References (44)

1. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T (1998) 123I-beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 105: 1213-1228
2. Berendse HW, Booj J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC (2001) Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense smell. Ann Neurol 50: 34-41
3. Ceravolo R, Volterrani D, Gambaccini G, Rossi C, Logi C, Manca G, Berti C, Mariani G, Murri L, Bonuccelli U (2003) Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurol Sci 24: 162-163
4. Chui HC, Teng EL, Henderson VW, Moy AC (1985) Clinical subtypes of dementia of the Alzheimer type. Neurology 35: 1544-1550
5. Chui HC, Lyness SA, Sobel E, Schneider LS (1994) Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 51: 676-681
6. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 24: 320-325
7. Ellis RJ, Caligiuri M, Galasko D, Thal LJ (1996) Extrapyramidal motor signs in clinically diagnosed Alzheimer disease [Review]. Alzheimer Dis Assoc Disord 10: 103-114
8. Fahn S, Elton RL, and Members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease. McMillan, New York, pp 153-163
9. Fischman AJ, Bonab AA, Babich JW, et al. (1998) Rapid detection of Parkinson's disease by SPECT with altropane selective ligand for dopamine transporters. Synapse 29: 128-141
10. Forstl H, Levy R, Burns A, Luthert P, Cairns N (1994) Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease - a hypothesis. Pharmacopsychiatry 27: 11-15
11. 18F-Flurodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 55: 1575-1577
12. Hughes A, Daniel S, Kilford L, Lees A (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease - a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
13. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ (1998) Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 19: 472-480
14. Kalra S, Bergeron C, Lang AE (1996) Lewy body disease and dementia. A review. Arch Intern Med 156: 487-493
15. Kazee AM, Cox C, Richfield EK (1995) Substantia nigra lesions in Alzheimer's disease and normal aging. Alzheimer Dis Assoc Disord 9: 61-67
16. Kemppainen N, Ruottinen H, Nagren K, Rinne JO (2000) PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 55: 205-209
17. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE (1997) Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 41: 368-374
18. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, Becker JT, DeKosky ST (1999) Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 53: 1292-1299
19. Lopez OL, Becker JT, Klunk W, et al. (2000) Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology 55: 1854-1862
20. Lopez OL, Becker JT, Kaufer DI, Hamilton RL, Sweet RA, Klunk W, DeKosky ST (2002) Research evaluation and prospective diagnosis of Dementia with Lewy Bodies. Arch Neurol 59: 43-46
21. Love S, Wilcock GK, Matthews SM (1996) No correlation between nigral degeneration and striatal plaques in Alzheimer's disease. Acta Neuropathol (Berl) 91: 432-436
22. Mayeux R, Stern Y, Spanton S (1985) Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 35: 453-461
23. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944
25. Mortimer JA, Ebbitt B, Jun SP, Rinch MD (1992) Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 42: 1689-1696
26. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN (1995) Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 37: 300-312
27. Nazarali AJ, Reynolds GP (1992) Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 12: 581-587
28. Perry EK, Marshall E, Thompson P, et al. (1993) Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm [PD-Sect] 6: 167-177
29. Piggott MA, Marshall EF, Thomas N, et al. (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's disease: a rostro-caudal distribution. Brain 122: 1449-1468
30. Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, Battistin L (1996) Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology 47: 1065-1068
31. Reisine TD, Soubrie P, Ferron A, Bias C, Romo R, Glowinski J (1984) Evidence for a dopaminergic innervation of the cat lateral habenula: its role in controlling serotonin transmission in the basal ganglia. Brain Res 308: 281-288
32. Rinne JO, Sahlberg N, Ruottinen H, Nagren K, Lehikoinen P (1998) Striatal uptake of the dopamine reuptake ligand 11C-beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50: 152-156
33. Sahlberg N, Marjamaki R, Rinne JO (1998) Different pattern of reduction of striatal dopamine reuptake sites in Alzheimer's disease and ageing: a post-mortem study with [3H]CFT. Neurobiol Aging 19 [Suppl 4S]: S242
34. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K (2000) Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 57: 205-208
35. Seeman P, Bzowej NH, Guan HC, et al. (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1: 5.15
36. Stern Y, Liu X, Albert M, Brandt J, Jacobs DM, Del Castillo-Castaneda C, et al. (1996) Modeling the influence of extrapyramidal signs on the progression of Alzheimer disease. Arch Neurol 53: 1121-1126
37. Tabaton M, Schenone A, Romagnoli P, Mancardi GL (1985) A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. Acta Neuropathol (Berl) 68: 218-223
38. Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, Kazis A (2001) Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom. Am J Alzheimers Dis Other Demen 16: 268-278
39. Tyrrell PJ, Sawle GV, Ibanez V, Bloomfield PM, Leenders KL, Frackowiak RS, Rossor MN (1990) Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type. Arch Neurol 47: 1318-1323
40. Victoroff J, Zarow C, Mack WJ, Hsu E, Chui HC (1996) Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch Neurol 53: 428-434
41. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL (1997) Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 24: 609-614
42. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL (2002) Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73: 134-140
43. Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA (2003) Parkinsonian like signs and risk of incident Alzheimer's disease in older persons. Arch Neurol 60: 539-544
44. Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, Kopp U (1991) Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 48: 619-624